公司资料
Graphite Bio 股价、新闻与催化剂
- 股票代码:
- GRPH
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for GRPH.
公司概览
业务概览
Graphite Bio was a gene-editing company focused on precision genome correction before its public-market wind-down. Its story was built around advanced editing science and rare-disease targets.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ before restructuring, Graphite sat in gene-editing biotechnology.
商业模式特征
The business depended on clinical and translational validation, as well as the feasibility of its editing approach.
生物医药行业定位
Graphite Bio is now best treated as a historical gene-editing case rather than a live catalyst name.
未来催化剂
- Graphite Bio is now mostly a legacy and closeout story, so the catalysts are any strategic or asset-disposition update rather than fresh pipeline news. The market no longer treats it like a live standalone development story.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。